119 results about "Hepatic lipid" patented technology

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention discloses a lactobacillus plantarum strain from healthy people in a cold region and application of the lactobacillus plantarum strain. The lactobacillus plantarum strain is named as PL-H1, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22286. The lactobacillus plantarum PL-H1 screened by the invention can obviously relieve the disease index, intestinal canal pathological change, inflammatory response and the like of an inflammatory bowel disease (IBD) model mouse. Moreover, compared with a standard strain WCSF1, the strain has the high metabolism characteristic of tryptophan and the function of adjusting the metabolism of IBD host intestinal tryptophan, and the curative effect of preventing and treating IBD is more remarkable. In addition, the lactobacillus plantarum strain PL-H1 can also improve the liver lipid accumulation and NAFLD activity of MCD fed mice, improve the blood lipid level and liver injury of the MCD fed mice and prevent liver fibrosis of the MCD fed mice, can be used for preventing and treating fungal infection related diseases, and is good in safety.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

The invention discloses preparation of plantain herb polysaccharide and application of plantain herb polysaccharide in preparation of medicine for preventing and treating fatty liver hemorrhagic syndrome of laying hens, and belongs to the technical field of biological medicine. The invention also provides application of the plantain herb polysaccharide in preparation of a feed additive for regulating and / or treating fatty liver of laying hens. According to the application disclosed by the invention, through in-vivo and in-vitro experimental modeling and detection of related indexes, the prevention and treatment effects of plantain herb polysaccharides with different doses on laying hen fatty liver caused by high-energy low-protein daily ration are comprehensively discussed, and hepatic lipid deposition is reduced by regulating hepatic lipid synthesis and oxidative catabolism as well as ferroptosis related signal channels; therefore, the laying hen fatty liver hemorrhagic syndrome induced by high-energy low-protein daily ration is effectively prevented and treated. The invention also researches the prevention and treatment effects of the plantain herb polysaccharide on the egg yield of laying hens and the fatty liver, and finds that the plantain herb polysaccharide can improve the egg yield of the laying hens and improve the production performance.

The invention relates to the technical field of biotechnology and gene function and application, and provides application of SNHG8 in preparation of drugs for preventing and treating non-alcoholic fatty liver diseases. The medicine is used for preventing and treating the non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The SNHG8 is applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, the medicine can effectively reduce the content of triglyceride in the liver by promoting SNHG8 gene expression, liver lipid accumulation increase and lipid metabolism related protein expression up-regulation induced by high-fat and high-cholesterol diet are relieved, and therefore the non-alcoholic fatty liver disease is prevented, treated or relieved. The purpose of preventing and treating the non-alcoholic fatty liver disease is achieved.

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating glycolipid metabolic diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-19 parts of coptis chinensis, 10-15 parts of rhodiola rosea, 10-20 parts of gynostemma pentaphylla, 9-12 parts of kapok, 10-15 parts of soapberry, 9-15 parts of salvia miltiorrhiza, 10-15 parts of rhizoma alismatis, 9-12 parts of oriental wormwood, 9-12 parts of radix bupleuri, 5-10 parts of semen cassiae, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of hawthorn, 6-9 parts of polygonum cuspidatum and 5-10 parts of fructus aurantii. The traditional Chinese medicine composition disclosed by the invention has the effects of inhibiting hyperlipidemia, hyperglycemia and hepatic lipid accumulation and relieving insulin resistance, and has a remarkable curative effect on relieving and treating glycolipid metabolic diseases.

The invention provides a salix soongarica flower extract and application thereof in preparation of weight-losing products, and belongs to the technical field of extraction of effective components of Chinese herbal medicines. According to the present invention, the product extracted from the soongarica soongarica flower through 70% alcohol and subjected to rotary evaporation concentration has effects of high fat diet induced animal weight reducing, liver lipid accumulation improving and liver inflammation improving, can be used for preparing the fat reducing product, and has good market application prospects.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The invention relates to the technical field of health food, in particular to a selenium tea ethanol dehydrogenase activating peptide composition as well as a preparation method and application thereof. A response surface method is adopted to optimize a TSE-PP preparation process, affinity ultrafiltration and LC-MS / MS technologies are utilized to screen ADH binding peptides, and the action mechanism of the ADH binding peptides is researched through molecular docking and animal experiments. Experiments prove that the TSE-PP can promote ethanol metabolism, relieve liver cell injury, inhibit inflammatory response, relieve oxidative stress and improve liver lipid accumulation, the high-dose use effect is more remarkable, and a scientific basis is provided for application of the TSE-PP in the food with the function of dispelling the effects of alcohol and the nutrition fortified product. The invention discloses the preparation process of the TSE-PP and the anti-alcohol and liver protection effects of the TSE-PP, meanwhile, the TSE-PP has good food processing characteristics, and a theoretical basis and an experimental support are provided for production and application of the TSE-PP in functional foods.

The invention relates to application of Ago2 in preparation of medicines for treating fatty liver or hyperlipemia and a product of the Ago2, belonging to the field of biological medicines. The invention provides an application of Ago2 in preparation of a medicine for treating fatty liver, and provides a medicine for treating fatty liver or hyperlipidemia and a preparation method thereof based on the new application of Ago2, and a protein, a gene, a recombinant expression vector and a transformant with the effect of treating fatty liver or hyperlipidemia. Animal experiments prove that the Ago2-based medicine for resisting fatty liver or hyperlipemia can remarkably reduce the liver lipid and blood fat content of animals with fatty liver caused by high fat, and the effective effect of resisting fatty liver or hyperlipemia is achieved.

The present invention discloses the application of the combined drug of mecobalamin (MeCbl) and Shuilinjia (SC) in the treatment of non-alcoholic steatohepatitis (NASH). The present invention firstly proposes that oral MeCbl can effectively intervene in and treat the progression of NASH disease, and firstly proposes that the combined drug of oral MeCbl and SC can synergistically enhance the treatment of NASH, as well as liver injury, inflammation, liver fibrosis and hepatic lipid deposition on the basis of monomeric drugs. The MeCbl / SC composition in the present invention has a potent effect on the treatment of NASH, provides a new therapeutic drug for such refractory liver diseases clinically, while reducing the single-drug use dose of SC, and reducing the incidence of adverse reactions and treatment costs of patients. The pharmacokinetics and safety data of the drug molecules involved in the present invention are relatively detailed, and the development of new indications can quickly enter clinical evaluation, saving development costs while shortening the R & D cycle.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present application relates to a new use of Fuling Gancao Decoction, and specifically discloses application of Fuling Gancao Decoction in treatment of hyperlipidemia, wherein the Fuling Gancao Decoction is composed of the following components in parts by weight: Fuling 2 parts, Guizhi 2 parts, Zhigancao 1 part and Shengjiang 3 parts. It is found through animal experiment research that the Fuling Gancao Decoction can improve the symptoms of hyperlipidemia rats, reduce the content of TG, TC and LDL-C in serum, improve the liver lipid, blood sugar of hyperlipidemia model animals, reduce the liver coefficient, improve the liver cell fatty degeneration, reverse the pathological morphology of adipose tissue cells and the mitochondrial damage of hyperlipidemia model animals. A new indication of the Fuling Gancao Decoction is found, the development of traditional Chinese medicines is promoted, and a new drug composition with less side effects is provided for treatment of hyperlipidemia.

This invention discloses a traditional Chinese medicine composition, preparation method, and application with lipid-lowering and intestinal flora-regulating effects, belonging to the field of traditional Chinese medicine technology. The raw material components are: 10-20 parts mulberry leaf, 10-20 parts immature bitter orange, 10-20 parts plantain, 8-15 parts lotus leaf, 8-16 parts medicated leaven, and 8-15 parts poria cocos. Based on the etiology and pathogenesis of obesity, this invention adopts a formula based on the principles of eliminating dampness and phlegm, lowering lipids and clearing turbidity. In addition to changing the obese phenotype, it focuses on balancing the body's internal organs and blood, strengthening the spleen and replenishing qi, resolving phlegm and eliminating dampness, supplemented by promoting qi circulation and digestion, lowering lipids and eliminating phlegm, thereby regulating the body's overall function, accelerating the decomposition of excess fat, and achieving the goal of weight loss by lowering lipids and regulating intestinal flora. Pharmacological experiments have shown that oral administration significantly improves weight gain and liver lipid accumulation induced by a high-fat diet in rats, resulting in clearer liver cord structure, denser cell arrangement, reduced lipid vacuolation and ballooning degeneration, and altering the composition and function of the intestinal microbiota.

The invention discloses application of PFKFB3 in preparation of a medicine for diagnosing, preventing or treating fatty liver. According to the invention, PFKFB3 plays an important role in diagnosis and treatment of fatty liver, especially non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Researches prove that the deficiency of PFKFB3 can lead to abnormal accumulation of liver lipid, aggravated inflammation level and aggravated fibrosis degree. The PFKFB3 can be used as a drug target for screening, diagnosing and treating the non-alcoholic fatty liver disease, and an accelerant of the PFKFB3 can be used for preparing drugs for preventing and treating the non-alcoholic fatty liver disease.

The invention discloses a Lactobacillus paracasei strain capable of converting licorice and enhancing the licorice to relieve lipid accumulation, oxidative damage and inflammatory response, and belongs to the technical field of microorganisms and the technical field of medicines. The lactobacillus paracasei CCFM1361 can convert glycyrrhizic acid, increase the content of glycyrrhetinic acid, glycyrrhetinic acid 3-O-glucuronide, ursolic acid and other substances, and increase the efficacy of the licorice extract, which is specifically embodied in (1) inhibiting the weight gain of high fat diet mice; (2) reducing liver lipid accumulation and lesion caused by the liver lipid accumulation; (3) the anti-oxidation level of the liver of the high-fat diet mouse is improved; (4) the inflammatory reaction caused by lipid accumulation is improved; and (4) reducing the inflammation level of the organism by activating an NF-kappa B p65 related pathway. Therefore, the lactobacillus paracasei CCFM1361 and glycyrrhizic acid have huge application prospects in production of products with the efficacy of resolving lipid accumulation and oxidative damage and inflammatory reaction caused by lipid accumulation.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The invention discloses a medicine for treating non-alcoholic fatty liver disease, the medicine comprises MIF-Anagonist V and p425, according to the medicine for treating the non-alcoholic fatty liver disease, by injecting the MIF-Anagonist V and the p425, the weight, blood sugar, blood fat and liver lipid deposition can be effectively improved, liver injury is avoided, and a novel medicine which is small in side effect and remarkable in curative effect is provided for NAFLD.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The invention relates to the technical field of biological medicines, in particular to application of cinnamyl glycine in preparation of products for predicting or preventing and treating metabolism-related fatty liver diseases. The present invention is based on the prevention and / or treatment of metabolism-related fatty liver diseases and related conditions thereof on the basis of cinnamoylglycine. Experimental results show that the cinnamyl glycine can effectively predict the risk of metabolism-related fatty liver diseases and high-risk metabolism-related fatty hepatitis of community population; cinnamoylglycine intervention can effectively reduce the weight, the triglyceride level and the cholesterol level of mice induced by high-fat and high-cholesterol diet, and improve liver lipid deposition, inflammatory cell infiltration and liver cell ballooning. Cinnamoylglycine can improve metabolism-related fatty liver diseases by inhibiting FDPS expression and activity. The invention provides a new effective intervention thought and means for metabolism-related fatty liver diseases and related diseases thereof.

The present application relates to the field of biomedicine technology, and in particular to the use of cinnamoylglycine in the preparation of products for predicting or preventing metabolic-related fatty liver disease. The present invention is based on the use of cinnamoylglycine to prevent and / or treat metabolic-related fatty liver disease and its related conditions. Experimental results show that: cinnamoylglycine can effectively predict the risk of metabolic-related fatty liver disease and high-risk metabolic-related fatty liver hepatitis in community populations; cinnamoylglycine intervention can effectively reduce the body weight, triglyceride and cholesterol levels of mice induced by a high-fat and high-cholesterol diet, and improve liver lipid deposition, inflammatory cell infiltration and hepatocyte ballooning; cinnamoylglycine improves metabolic-related fatty liver disease by inhibiting the expression and activity of FDPS. The present invention provides new and effective intervention ideas and means for metabolic-related fatty liver disease and its related conditions.

The invention discloses a shRNA interference library for inhibiting ETS2 expression and application thereof, and belongs to the technical field of gene drugs. The shRNA interference library for inhibiting ETS2 expression comprises one or more of a sequence shRNA1 as shown in SEQ ID NO. 1, a sequence shRNA2 as shown in SEQ ID NO. 2 and a sequence shRNA3 as shown in SEQ ID NO. 3. The expression of the ETS2 gene in the liver is specifically inhibited by adopting an shRNA interference mode, the liver injury induced by high fat diet can be obviously inhibited, and the liver lipid accumulation of a mouse is also obviously improved, so that the interference of the expression of the ETS2 in the liver can inhibit the lipid accumulation of the mouse and obviously alleviate the liver injury of a fatty liver disease patient.

This invention discloses the use of the SLC7A5 gene or its encoded product as a target in the preparation of drugs for the prevention and / or treatment of metabolic dysfunction-related fatty liver disease (MASLD). This invention reveals for the first time that SLC7A5 is a key node regulating hepatic lipid metabolism, and inhibiting its expression or function can significantly reduce hepatic steatosis, inflammation, and fibrosis. Specifically, this invention relates to pharmaceutical compositions containing SLC7A5 inhibitors, said inhibitors including small molecule compounds, specific antibodies, nucleic acid interfering agents, or gene editing tools. Furthermore, this invention provides a drug screening method for MASLD, which combines molecular docking virtual screening technology with target specificity verification steps, and the application of SLC7A5 as a biomarker in disease diagnosis, staging, and efficacy monitoring. This invention provides definite new targets and candidate drugs with well-defined mechanisms for the clinical diagnosis and treatment of MASLD.

The invention belongs to the technical field of biological medicine, and particularly relates to application of recombinant Glypican 1 protein in treatment of non-alcoholic steatohepatitis. The Glypican 1 protein can treat non-alcoholic steatohepatitis for the first time, experiments prove that the Glypican 1 protein can improve liver lipid deposition, inflammation, fibrosis and other key pathological characteristics, and particularly, after the serum GPC1 level is increased, the Glypican 1 protein can inhibit high-fat and high-cholesterol diet induced mouse body weight increase, optimize the ratio of liver tissue weight to body weight, and improve the non-alcoholic steatohepatitis. The glucose tolerance and the insulin sensitivity are improved, so that the metabolic disorder is integrally improved; besides, the GPC1 accelerant can directly target macrophages, inhibit expression of pro-inflammatory genes (such as Tnf and Nos2) and relieve cascade reaction of liver inflammation, the anti-inflammatory effect is achieved by inhibiting an ERK1 / 2 phosphorylation pathway in mechanism, an innovative, efficient and flexible solution is provided for NASH treatment on the whole, and the defects of current treatment means are overcome.

The invention discloses an application of clofampol in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease, and belongs to the technical field of medicines. It is found that the clofamprol can reduce the liver index, effectively improve liver lipid metabolism disorder, inhibit hepatic cell fatty degeneration, inflammatory response and fibrosis processes, reduce the level of alanine transaminase, aspartic transaminase, total bilirubin, triglyceride and low-density lipoprotein, improve the level of albumin and high-density lipoprotein, and inhibit liver cell fatty degeneration, inflammatory response and fibrosis processes. Therefore, effective treatment on the non-alcoholic fatty liver is realized.